Averywell provides a non‑invasive, blood‑based liquid biopsy that detects early‑stage lung cancer by profiling circulating miRNA signatures with AI‑driven analysis. The test delivers high‑sensitivity results quickly via a cloud platform, enabling primary care and hospital screening programs to identify at‑risk individuals—including both smokers and non‑smokers—without the need for costly imaging. This approach aims to expand access to lung cancer screening, reduce late‑stage diagnoses, and lower overall healthcare costs.
Funding
$430K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early-stage lung cancer often goes undetected because current screening methods rely on imaging such as CT scans, which are expensive, involve radiation exposure, and are typically limited to high‑risk smokers. This results in delayed diagnosis, higher treatment costs, and increased mortality for both smokers and non‑smokers.
Solution
Averywell offers a non‑invasive liquid biopsy that detects lung cancer by profiling circulating microRNA (miRNA) signatures in a simple blood draw. The test uses proprietary miRNA biomarkers combined with AI‑driven analysis to achieve high sensitivity and specificity for early tumor detection. By eliminating the need for imaging, the assay can be administered in primary care or community settings, expanding access to screening for at‑risk populations regardless of smoking status. Results are delivered quickly through a secure cloud platform, enabling clinicians to initiate timely diagnostic follow‑up and treatment planning. The technology aims to reduce avoidable deaths and lower overall healthcare costs associated with late‑stage lung cancer care.
Target Audience
Primary customers are healthcare systems, hospitals, and diagnostic laboratories that conduct lung cancer screening, as well as public health programs seeking cost‑effective, wide‑reach early detection solutions.
Features
- Blood‑based miRNA liquid biopsy that identifies lung cancer signatures without radiation exposure
- AI and machine‑learning algorithms that interpret miRNA profiles to deliver highly accurate early‑detection results
- Scalable testing workflow suitable for primary care offices, hospitals, and large‑scale screening programs
- Cloud‑hosted reporting dashboard providing clinicians with clear risk scores and actionable insights
- Inclusive assay design validated for both smokers and non‑smokers, supporting equitable screening across diverse populations